Companies will now be in the process of assessing the impact of the industry's new agreements on their portfolio of already reimbursed medicines and even their late-stage pipelines.
Companies assess price cut impact and look ahead to April 2023
September 13, 2021 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New report highlights widening gap in access to modern medicines between Australia and NZ
October 8, 2025 - - Latest News -
RACGP warns of mounting pressure on GPs as costs and complexity rise
October 7, 2025 - - Other Health -
AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector
October 7, 2025 - - Australian Biotech -
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 - - Latest News -
MTPConnect and Wholesale Investor unite to accelerate investment in life sciences sector
October 7, 2025 - - Australian Biotech -
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 - - Australian Biotech -
FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial
October 7, 2025 - - Australian Biotech